Literature DB >> 14764622

The genetic basis of systemic lupus erythematosus--knowledge of today and thoughts for tomorrow.

Ludmila Prokunina1, Marta Alarcon-Riquelme.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic rheumatic disease with an autoimmune etiology. Nuclear components of the cells are the main targets of the autoimmune reaction, affecting virtually any organ in the body. SLE is also called a prototype disease due to a substantial overlap in its clinical symptoms with other autoimmune diseases. Therefore the understanding of the mechanisms underlying SLE may contribute to advances in studies and development of new treatments for several autoimmune diseases. SLE is a complex disease with both genetic factors (mutations or susceptibility alleles) and environmental factors (infections, drugs, stress, exposures, etc.) contributing to its development. In this article we will give an overview of the latest findings in genetics of SLE, concentrating on the two most interesting and promising pathways: the PD-1 and the interferon pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764622     DOI: 10.1093/hmg/ddh076

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  16 in total

Review 1.  CD24: from a Hematopoietic Differentiation Antigen to a Genetic Risk Factor for Multiple Autoimmune Diseases.

Authors:  Yixin Tan; Ming Zhao; Bo Xiang; Christopher Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

2.  Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan.

Authors:  Shu-Chen Wang; Yi-Jing Chen; Tsan-Teng Ou; Cheng-Chin Wu; Wen-Chan Tsai; Hong-Wen Liu; Jeng-Hsien Yen
Journal:  J Clin Immunol       Date:  2006-10-06       Impact factor: 8.317

3.  Association between CTLA-4 exon-1 +49A/G polymorphism and systemic lupus erythematosus: an updated analysis.

Authors:  Wei-Wei Chang; Liu Zhang; Ying-Shui Yao; Hong Su
Journal:  Mol Biol Rep       Date:  2012-06-21       Impact factor: 2.316

4.  Identification of molecular biomarkers for multiple sclerosis.

Authors:  Sallyanne C Fossey; Cindy L Vnencak-Jones; Nancy J Olsen; Subramaniam Sriram; Gladys Garrison; Xenquing Deng; Philip S Crooke; Thomas M Aune
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

Review 5.  Genes and Sjögren's syndrome.

Authors:  Beth L Cobb; Christopher J Lessard; John B Harley; Kathy L Moser
Journal:  Rheum Dis Clin North Am       Date:  2008-11       Impact factor: 2.670

6.  Hepatoma cells up-regulate expression of programmed cell death-1 on T cells.

Authors:  Ji Chen; Xue-Jie Wu; Gui-Qiang Wang
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

7.  Monocyte chemoattractant protein-1 -2518 A/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE.

Authors:  Piotr Piotrowski; Margarita Lianeri; Robert Gasik; Andrzej Roszak; Marzena Olesińska; Paweł P Jagodziński
Journal:  J Biomed Biotechnol       Date:  2010-04-21

Review 8.  The candidate gene approach: have murine models informed the study of human SLE?

Authors:  D S Cunninghame Graham; T J Vyse
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

9.  Occurrence of organ-specific and systemic autoimmune diseases among the first- and second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews.

Authors:  Marta Mosca; Linda Carli; Anna d'Ascanio; Chiara Tani; Rosaria Talarico; Chiara Baldini; Laura Bazzichi; Antonio Tavoni; Paola Migliorini; Stefano Bombardieri
Journal:  Clin Rheumatol       Date:  2008-05-29       Impact factor: 2.980

10.  Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Authors:  Napoleon Bellua Sam; Qin Zhang; Bao-Zhu Li; Xiao-Mei Li; De-Guang Wang; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2020-02-24       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.